Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Reaches New 12-Month Low at $52.25

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF – Get Free Report) hit a new 52-week low on Friday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25. Recordati Industria Chimica e Farmaceutica Stock Performance [...]

featured-image

Shares of Recordati Industria Chimica e Farmaceutica S.p.A.

( OTCMKTS:RCDTF – Get Free Report ) hit a new 52-week low on Friday . The company traded as low as $52.25 and last traded at $52.



25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Recordati Industria Chimica e Farmaceutica Stock Performance The company has a market cap of $10.78 billion, a price-to-earnings ratio of 18.80 and a beta of 0.

33. The firm’s 50 day simple moving average is $52.12 and its 200-day simple moving average is $51.

78. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.

95 and a current ratio of 1.36. Recordati Industria Chimica e Farmaceutica ( OTCMKTS:RCDTF – Get Free Report ) last posted its quarterly earnings results on Tuesday, July 30th.

The company reported $0.70 earnings per share for the quarter. The firm had revenue of $622.

00 million for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.

78%. About Recordati Industria Chimica e Farmaceutica Recordati Industria Chimica e Farmaceutica S.p.

A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments.

Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. Featured Articles Five stocks we like better than Recordati Industria Chimica e Farmaceutica 3 Grocery Stocks That Are Proving They Are Still Essential Can Costco Stock Hit New Highs as Interest Rates Drop? How to Calculate Options Profits These 3 Stocks Show How to Navigate Declining Consumer Confidence Low PE Growth Stocks: Unlocking Investment Opportunities MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy? Receive News & Ratings for Recordati Industria Chimica e Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica e Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter .

.